‘Sussing that doctor out.’ Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study by Scarborough, Jane et al.
RESEARCH ARTICLE Open Access
‘Sussing that doctor out.’ Experiences and
perspectives of people affected by hepatitis
C regarding engagement with private
general practitioners in South Australia: a
qualitative study
Jane Scarborough1* , Emma Ruth Miller1, Paul Aylward1 and Jaklin Eliott2
Abstract
Background: Australians with chronic hepatitis C (HCV) can access affordable Direct Acting Antiviral (DAA) treatments
with high cure rates (>90%), via General Practitioners (GPs). Benefits from this treatment will be maximised if people
with HCV readily disclose and engage with private GPs regarding HCV-related issues. Investigating the perceptions and
experiences of people affected by HCV with GPs can allow for this pathway to care for HCV to be improved.
Methods: In 2013–2014, 22 purposively sampled participants from South Australia (SA) were interviewed. They a) had
contracted or were at risk of hepatitis C (n = 10), b) were key workers who had clients affected by HCV (n = 6), and c)
met both a) and b) criteria (n = 6). The semi-structured interviews were recorded, transcribed and thematically analysed.
Results: People affected by HCV viewed GPs as a source of general healthcare but, due to negative experiences and
perceptions, many developed a strategy of “sussing” out doctors before engaging with and disclosing to a GP regarding
HCV-related issues. Participants were doubtful about the benefits of engagement and disclosure, and did not assume
that they would be provided best-practice care in a non-discriminatory, non-judgemental way. They perceived risks to
confidentiality and risks of changes to the care they received from GPs upon disclosure.
Conclusion: GPs may need to act in ways that counteract the perceived risks and persuade people affected by HCV of
the benefits of seeking HCV-related care.
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Background
Up to 249,000 Australians, representing more than 1%
of the Australian population, are estimated to be chron-
ically infected with hepatitis C virus (HCV), with
approximately 28% undiagnosed [1]. HCV transmission
occurs by blood-to-blood contact and, in Australia, most
commonly through illicit injecting drug use [2]. A range
of symptoms is associated with chronic HCV infection
which, without antiviral treatment, can lead to liver
damage and, potentially, hepatocellular carcinoma [1].
Reducing the impact of HCV requires increased rates of
diagnosis and increased uptake of antiviral treatment [2].
The uptake rate in Australia for antiviral treatments
for HCV has dramatically improved from as few as 2%
in 2012 [3] of those infected entering treatment to 14%
in 2016 with advances in treatment [4]. Previous
available antiviral treatments for HCV in Australia were
pegylated interferon-based, involved complicated
medication regimes, severe side effects, long treatment
periods and variable rates of cure [5]. New direct acting
antiviral (DAA) treatments for HCV have achieved viral
clearance (representing a cure) in more than 90%, with
reduced treatment time and few side effects [6]. From
March 2016 DAA treatments approved for use in
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Australia were included on the pharmaceutical benefits
scheme (PBS), which subsidises treatment, making these
treatments affordable for Australian citizens [7].
Australian General Practitioners (GPs) are well placed,
professionally and geographically [8], to be involved in
HCV diagnosis, prescribing antiviral treatment and referral
to specialists for HCV [9–13]. Australia provides universal
access to general practice, with the Federal Government
subsidising fee-for-service payments through the Medicare
program [14] and approximately 80% of Australians access
general practice annually [15]. Most people diagnosed with
HCV in Australia are diagnosed by GPs [16] and since the
introduction of the new DAA for HCV 19% [4] of those
treated have had this prescribed by GPs. The majority of
people with HCV are expected to be prescribed DAA for
HCV by GPs [17–21] and GP involvement in prescribing
is necessary due to the limited capacity of specialists to
meet demand for treatment [22].
However, barriers to GPs being involved in this work
have been reported [23–25] with findings indicating that,
in addition to addressing system barriers, there was a need
for additional capacity building for GPs. HCV education to
optimally equip GPs for this role has been proposed [24–
26] and this education could benefit by including a consid-
eration of perspectives of people affected by HCV [27].
Several studies have examined the barriers and facilita-
tors to seeking HCV-related care amongst a range of popu-
lations, various settings, and at different stages of the
cascade of care [5, 28–31]. Reported barriers to treatment
access include negative patient perceptions of biomedical
factors such as counter indications, side effects, and poor
efficacy [31] – many of which relate to older, Interferon
based treatments. Although these factors may be alleviated
with the new antiviral treatments for HCV, HCV-affected
people need to be aware of these advances [32], and
remaining barriers may deter HCV-infected people from
seeking treatment.
The association with injecting drug use often results in
stigma being attached to a HCV diagnosis [33, 34].
People with HCV and people who inject drugs have
reported negative experiences when seeking healthcare,
and their perceptions are that this is due to stigma [35–
41]. Indeed, several studies have demonstrated that some
GPs hold negative views of people with HCV based on
the association of the virus with injecting drug use [33,
34, 42]. This can adversely affect the nature of care pro-
vided and, subsequently, the extent to which care is
sought for HCV [8, 43].
People with HCV or HCV-related issues in Australia
may access GPs for their healthcare [15] but for care
specific to HCV-related issues to be provided, the GP
needs to be aware of the patient’s HCV status or risk
factors for HCV. There is no requirement for individuals
to be registered with a GP or general practice in
Australia [44], so patients are free to move between GPs.
As no comprehensive electronic patient record system
exists in Australia [44], GPs must rely on information
provided by the patient. Some patients may disclose
current illicit drug use to GPs to seek help for this issue
[45]. Other patients may intentionally hide their current
drug use from GPs to avoid stigmatisation [8, 46] or to
enable ‘doctor shopping’ or ‘drug seeking’ for drugs to
be used for non-medical purposes [47]. For those whose
only indicator of past drug use may be HCV, disclosure
of their past history is a matter of choice [39]. Where a
GP is aware of a patient’s HCV status, other health
issues may be prioritised by the GP or by the patient.
Although GPs have been included as participants in
previous HCV studies, these studies have not focused on
the perception of care provided to the diverse range of
people who would present to GPs with HCV health-
related issues. Our study used qualitative methodology to
investigate the perspectives and experiences of people
affected by HCV with private GPs in Australia and the
effect that the interactions have on perceptions about
engaging with GPs about HCV-related issues. The insights
gained could improve people’s engagement with GPs about
issues related to HCV, encourage uptake and adherence to
DAA treatments, and more efficiently reduce the preva-
lence of this blood-borne virus in Australia.
Methods
Sample and recruitment
We used a purposive sampling strategy to gain a range
of perspectives regarding individuals who potentially
access HCV care in private general practice in South
Australia (SA). Three groups were recruited (see Fig. 1).
The first included people either at risk for, or self-report-
ing, a diagnosis of HCV (identified as “A”: affected by
HCV). This included participants with a history of illicit
injecting drug use but not currently diagnosed with
HCV, who are at risk of becoming infected, or may be















Fig. 1 Final Sample
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who remain undiagnosed [2]. People affected by HCV in
this way can provide valuable insights into their perspec-
tives and experiences about the provision of care by pri-
vate GPs.
The second group comprised key workers providing
care to clients affected by HCV (identified as “CA”:
clients affected) including clinicians and peer workers;
these individuals can provide valuable insights about
care sought and provided on the basis of their long
engagement with, and advocacy for, clients affected by
HCV. These two groups: “affected by HCV” and the
“clients affected” were not discrete, however, as some
key workers reported personal experience of a diagnosis
of HCV and illicit injection drug use histories (identified
as “A+CA”: affected by HCV, with clients affected by
HCV). These participants were able to give perspectives
based upon their own, and their clients' experiences.
Purposive sampling further aimed to include participants
varying in drug use status, awareness of HCV, duration
of infection, and treatment status.
Recruitment occurred in three phases and primarily
through two organisations, Drug and Alcohol Services of
South Australia (DASSA) and Hepatitis SA. DASSA is
an agency of the SA Health Department with clinics
offering a variety of services including clean needle
provision, opioid substitution therapy (OST) and drug
counselling. Hepatitis SA is a community organisation
that provides information and advocacy services, including
peer education, for people affected by viral hepatitis.
Recruitment of key workers from DASSA and Hepatitis
SA occurred through targeted emails, as well as researcher
attendance at staff meetings. Key workers targeted for
recruitment included medical practitioners, nurses, social
workers, psychologists, and peer educators. To recruit
people affected by HCV, an advertisement was placed in
the quarterly Hepatitis SA newsletter, distributed through-
out SA in both hardcopy and digital form. Recruitment
targeting people who had a history of injecting drug use
occurred through DASSA clinics via the placement of
posters and information packs, and subsequent personal
approaches at the clinics. Eligible participants were older
than 18 years and able to participate in the interview in
English. Signed informed consent was obtained before
commencement of the interview.
Participants
Twenty-two participants were recruited (11 female, 11
male), 10 people affected by HCV (A), 6 people who have
clients affected by HCV (CA), and 6 who were both
affected by HCV and had clients affected by HCV (A+
CA). Other than indicating that they met the inclusion
criteria of being over 18 years of age, participants were
not asked to supply demographic details, but some demo-
graphic information was provided during the interviews.
Participant responses indicated an age range from early
20s to over 60. Most participants were residents of
Adelaide (the capitol of SA) metropolitan suburbs with
only one participant (CA) residing in a regional area and
one participant (A) previously residing in a regional area.
Participants with clients affected by HCV provided
services to HCV-affected clients across SA. One partici-
pant indicated a non-English speaking, 1st generation
migrant background. No participants identified to the
interviewer as an Indigenous Australian.
All participants reporting a diagnosis of HCV also
reported a history of illicit injecting drug use, and that
HCV transmission occurred via this practice, with the
exception of one participant who reported that transmis-
sion was via non-sterile tattooing. The significance of
this self-reported illicit drug use of participants varied in
regard to currency (from recent to historical) and
severity (chronic and relapsing, to occasional and
controlled). All affected participants indicated that they
had the choice to access private GPs, with some partici-
pants being currently highly engaged. Participants from
the groups affected by HCV, self-reported a range of
HCV diagnosis including current chronic HCV infec-
tion, intention to be tested, previous HCV infection
(naturally cleared), and cured of chronic HCV infection.
Participants from the groups affected by HCV also self-
reported a range of involvement in HCV treatment:
current, seeking treatment, successful and unsuccessful
completion of treatment, decided against interferon-
based treatment available at the time of the study.
Data collection and analysis
Semi-structured qualitative interviews were conducted
from November 2013 and August 2014, at a time when
DAA treatment in Australia was being clinically trialled
but yet to be approved for broader use or included on
the PBS. Interviews were carried in a range of settings
convenient to the participants, including DASSA sites,
public library spaces and a participant’s home. Interview
outlines were informed by the existing literature [5, 28–
31] and included questions about HCV knowledge (‘Tell
me how you gained your knowledge about hepatitis C’),
experience of HCV (‘Can you tell me the effect of hepa-
titis C on your life?’), perceptions of private GPs (‘What
for you makes a good private general practitioner?) and
experience of care provided by GPs (‘Can you describe
any situations where you have received medical care
from private GPs that relates to hepatitis C?’). Interviews
ranged in length from 19 min to 87 min with the median
length of 58 min. The interview outline was covered dur-
ing all interviews, although one participant requested the
interview was kept brief. Participants were given a $20
supermarket gift voucher as compensation for their time.
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Interview audio recordings were transcribed verbatim as
soon as possible after the interview took place. The tran-
scripts were de-identified with participant names replaced
with pseudonyms and the text entered into NVivo 10 soft-
ware [48]. Transcriptions were thematically analysed in
the process outlined by Braun and Clarke [49] to identify,
analyse, and report on participants’ perspectives of care
provided by GPs for HCV. The interview text was then
systematically coded, with some codes reflecting the
literature-informed interview topics and others reflecting
additional aspects of the experiences and perspectives of
participants. The codes produced were then initially
grouped to identify possible themes. The themes were
reviewed and discussed amongst the authors to define and
name the final themes reported. Pseudonyms used during
the analysis were removed from the manuscript to protect
participant confidentiality.
Reflexivity
The first author works at clinical sites offering treatment
for drug issues and in a role that involves interacting with
a variety of private GPs. Other members of the research
team were from a variety of professional backgrounds, and
provided an ‘outsider’ perspective, which promoted a
more reflexive analysis of the data Interpretation was en-
hanced through collective discussion and reflection upon
emerging themes identified by the first author. This en-
abled different lenses to be applied and interpretive mean-
ing across the data set to be agreed consensually. The
possible effect of any one individual’s bias was therefore
ameliorated by having input from the four authors
throughout the research process [49].
Ethics approval and considerations
Ethics approval was obtained from the South Australian
Health Human Research Ethics Committee, the Aboriginal
Health Research Ethics Committee (a sub-committee of
the Aboriginal Health Council of South Australia Inc.), and
the Human Research Ethics Committee of the University
of Adelaide.
The first author conducted the interviews and works at
DASSA in a non-clinical role. To avoid any potential ambi-
guity, [50] the interviewer explained her role as researcher
and her separate role at DASSA, and emphasized processes
to be used to protect confidentiality. Participant responses
indicated that they understood choice regarding participa-
tion and that participation would not affect their ongoing
relationships. The drug use and HCV status of researchers
has been presented as important aspect of prior research
in this field [51]. The interviewer has no history of illicit
drug use or HCV and was careful to present as having no
such history, allowing the participants’ decisions to be in-
volved in the research and share information to be based
on informed consent.
Results
The experiences and perceptions of participants regard-
ing engagement of people with HCV with GPs will be
outlined. Similar experiences and perceptions were
provided by participants independent of the basis of
their recruitment as people directly affected by HCV
(A), had clients affected by HCV (CA) or could provide
both perspectives (C + CA).
Engagement about HCV – Disclosure choices and
strategies
Participants viewed GPs as a source of general health-
care that potentially includes care for issues related to
HCV. Several participants stated that when they were
‘lucky’ to find a good doctor, they would attempt to con-
tinue to engage with them.
My doctor’s interested in what’s happening, asks me
the right questions. Asks me what testing I’d liked to
be done. Won’t write “hep C” on a referral to anyone
else, without my express consent. (A)
Some participants held that the benefit of engaging with
GPs could only be fully realised if they disclosed their
HCV positive status and/or drug use history, placed
their trust in the GPs professionalism, and were accept-
ing of the care they received.
You know if I’m sick I’m going to have to say “Might
be because …”. I want to go to find out; go to every
aspect of why I might be sick. (A)
Where they perceived a lack of benefit associated with
disclosure and a risk of consequences in disclosure
(either within the patient–doctor relationship, or in their
wider lives), people with HCV were cautious about
disclosing HCV. A process of judging or ‘sussing’ out
the GP before disclosing was repeatedly described.
So I think it would an issue of the client sussing that
doctor out and thinking “No I don’t think that they
could deal with that,” and I think they’re pretty good at
that. (CA)
I can tell what kind of character he is you know.
He would be one of those that just, you could just
see that. He would go out of his way, but as for
other doctors I’m not real sure about that you
know. (A)
… clients will just go to drop in, bulk-billing places at
times when they need something, and then they [the
client] may link with a GP if they [the client] find they
got on well with the person ….(CA)
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Often participants outlined that they or their clients
adopting a strategy of having one GP that they engage
with for HCV-related issues, but maintaining non-
disclosure with other GPs. Engagement with a nurse
trained to support people with HCV to gain appropriate
care in a shared care arrangement was also regarded as
an effective strategy to maximise care for HCV.
I go between a couple of GPs. I also go out and see
[name of doctor] out at [surgery that has blood borne
virus treatment specialty] and so yeah. He’s a lot more
reasonable. (A)
There’s a hep C place over at the [name of practice]
over there and that’s where my nurse is. You know
they’re pretty supportive there. (A)
Perception of engagement involving risk to
confidentiality of sensitive information
Engagement with GPs that involved disclosure of HCV
positive status was seen by some participants as a risk to
the confidentiality of this sensitive information, with poten-
tial serious consequences. Some participants had not
disclosed their HCV status to their work, families, or their
intimate partners. They reflected that their illicit drug use
was part of their past and that they should be in control of
the decision to disclose any of this information. These
participants said that they were not suspected of a past
drug history and that this history would remain secure if
they managed disclosure about HCV.
Well I still haven’t told my parents. (A+CA)
… my partner doesn’t know and I’ll never tell him. I
don’t think it’s relevant. (A+CA)
Possible breaches of confidentiality by medical practi-
tioners providing HCV-related care were seen to dimin-
ish the non-disclosure choice of people affected by
HCV. Participants described people affected by HCV as
being ‘on constant guard’ to protect this information.
The need for a person’s HCV status to be shared
between healthcare workers was questioned, as the
participants expected that all health practitioners should
use universal precautions to avoid transmission, and con-
sidered that this would negate the need to share this infor-
mation in most circumstances. Where breaches of
confidentiality had occurred, this led affected participants
to question whether the health practitioners involved in
their care understood the significance of their choice to
limit the disclosure of their HCV positive status.
… my kids got asked “Could you get your mum to
ring the hospital urgently?” and I’d made it really clear
I have not told anybody in my family about this, do
not leave messages. (A+CA)
I used to tell them [healthcare workers] because “it’s
my responsibility of blood you know, infectious
blood” and all that sort of thing. And then in at the
[name of hepatitis C support organisation] they said
“Well actually it is their responsibility. You don’t have
to tell anybody.” (A)
HCV-affected participants reported feeling discomfort
when their HCV status was recorded on patient re-
cords. They felt that the standard practices associated
with data collection and patient records presented a
risk to confidentiality and control of information.
Participants proposed that engagement with GPs was
affected by these concerns and that they, or their
clients, had not disclosed information, and indeed,
avoided returning to practices where they had reluc-
tantly disclosed.
Every worker can look up my records. Do I like that?
No I hate that with a passion. (A+CA)
… this form, this is really bad; this form goes to the
receptionist and the receptionist keeps it there, puts
whatever she wants, [it] sits on the receptionist’s desk
and then it gets given back to and given back to the
doctor. So this form is floating all around the place …
(A)
The understanding of the sharing of information was in-
formed by participants’ involvement in highly regulated
opioid substitution programs. One participant perceived
that this healthcare was only available on the condition
that they subjected themselves to the rules of the pro-
gram, including being tested for HCV, stating “I’ve got
to do a blood test soon” (A), and that information would
be electronically shared between the program and GPs,
as “It’s all linked” (A).
Perception of engagement involving risk of exposure to
discrimination, negative judgement and change to care
provided.
Based on their expectations and experiences, participants
did not assume that all GPs would be willing to provide
care for HCV-related issues in a non-discriminatory, non-
judgemental way. Participants stated they understood that
GPs could develop negative attitudes to people with a
drug history due to being exposed to ‘drug seeking’ or
‘doctor shopping’ behaviour, and categorised this reaction
by GPs as somewhat reasonable. The majority of partici-
pants detailed how they or their clients had participated in
these behaviours to obtain drugs to be used for non-
medical purposes.
But you can’t blame the GPs being like they are
because you’ve got no idea what some people do to
get drugs out of them. (A)
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Depending on the doctor you could pretty much talk
your way into getting anything you want, but if you
do want something in the future and you do actually
need it, they’re not going to give it to you if they’ve
found out you’ve lied ….(A)
Two participants described GP practices as ‘banning’ a
patient in response to patient bad behaviour and an ex-
pectation that if a patient was suspected of ‘doctor shop-
ping’ or ‘drug seeking,’ they may be banned. For one
patient, such a ban meant that there was no primary
health care available in the local area.
…of course when they [patients] act up then they’ve
got bans [from attending GP practices] and things like
that, so yes there are issues…. I’ve got one client in
[neighbouring rural town] that has been banned from
every clinic in [major rural centre] plus [neighbouring
rural town within travelling distance for client]. (CA)
One participant reported their perception there was a
hurdle of stigmatisation to overcome when telling a GP
about drug use, which, as a necessary step to getting
help, meant that help was therefore not assured. This
participant was affected by HCV and described ap-
proaching GPs for help for drug issues as part of the
process of engaging with them regarding HCV.
You don’t tell a doctor “I’m using drugs. Don’t help
me please.” It’s a cry out for help isn’t it? You know.
Like it means if you get ignored you’re like “What did
I bother telling them for?” Especially when it’s such a
frowned upon thing. (A)
Whilst overt discrimination by GPs based on HCV status
was not reported, a perception of subtle changes to GP
behaviour upon disclosure of HCV status was.
Yeah just her [the GP’s] whole attitude like really
changed towards, you know there wasn’t that kind
conversation anymore, yeah you know. (A)
Participants reported exposure to discrimination in other
healthcare settings and this exposure appeared to be in-
corporated into their perception of expected risk, and
increased their expectation, of discrimination from GPs.
… and he [surgeon] said “I see you’ve had treatment.”
And I said “Yeah but it didn’t work.” And it was like
he was on a rubber band, he flew back to the back of
his chair. … and then he came up with all these
excuses why I couldn’t have this operation. (A)
Participants also described experiencing a shift of attrib-
uted identity upon disclosure—from ‘patient’ to ‘drug-
addicted patient,’ with an associated change to the care
received. For instance, participants related that they were
prescribed drugs of dependence when their HCV status
was unknown, but that GPs would become extremely re-
luctant to prescribe these drugs once aware of their
HCV status. Some participants framed their past illicit
drug use as something that they had left behind and as
not requiring treatment. Offers by GPs for drug treat-
ment were considered by these participants as well-
intentioned, but misplaced and irrelevant.
If I said you know, had injected drugs in the past they
would always enquire whether I needed ‘rehabilitation’
and it was if ever I needed any pain relief, I broke a
rib once and the doctor said “I can’t give you anything
stronger than Panadol unless I send you off for an
X-ray.” (A+CA)
Some HCV-positive participants expressed fear of having
important aspects of their lives judged by GPs and other
healthcare workers. In particular, participants expressed
concern that their decision to have children would be
negatively judged due to the children being ‘exposed’ to
the risk of transmission through household or in-utero
transmission.
… I’ve heard some horror stories of what people have
you know experienced with GPs and hospitals, …
there’s even this feeling that you know you don’t
deserve to have children because you know the risk
that you’re putting them through ….(A)
Uncertainty about the benefit of engaging with GPs
about HCV – Based on perceived misinformation
provided and information gaps from GPs
Participants described that they and other people with
HCV had developed knowledge about HCV, sometimes
over the long duration since diagnosis. They proposed
that their HCV knowledge could sometimes exceed that
expected of their GPs: “I … found out what I could and
what I needed to know” (A). The difficulty of GPs keep-
ing abreast of all of the detail of the conditions that they
encounter was often acknowledged by participants.
… hep C [is] not fully understood by GPs and I’m not
blaming them for that, just ‘cause they’re trying to
grapple with so many attends [sic], that’s impossible. (A)
Some participants also acknowledged that they had mis-
understood what they had been told: “I didn’t under-
stand I had hep C” (A + CA).
Most participants reported that HCV-affected people
had accumulated experiences of being provided what they
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perceived to be inadequate or inaccurate information by
GPs in regard to HCV. This perception contributed to a
lack of certainty by participants that GPs would provide
accurate, up-to-date information regarding HCV. Some
participants spoke of errors by some GPs, which they
attributed to GPs limited knowledge about HCV testing,
sometimes leading to serious repercussions for patients. A
participant stated one of their clients was given a diagnosis
of HCV, which was subsequently found to be incorrect.
Another stated that they had been told that they had
cleared the virus when they had not.
… she believed she had hep C for over 12 years and
was in [rural town] and the GP had never done a PCR
test [polymerase chain reaction test that is need to
confirm active HCV infection]. (A+CA)
… I was told that my bloods functions were back to
normal and that I had cleared the virus. Not knowing
any different I believed it ….(A)
Some participants affected by HCV articulated previ-
ous gaps in their knowledge about transmission, and
suggested that GPs had missed opportunities during
consultations to provide such important information.
For example, it was reported that GPs did not provide
safe-injecting information to those patients they knew
injected illicit drugs, or provide information about
household transmission to people with a diagnosis of
HCV.
Just didn’t tell me how it was passed on or anything
like that. I’d been seeing this guy [GP] on and off for
20 years so he know [sic] all my background and
everything anyway so I suppose he didn’t even think
to mention anything to me ….(A)
Some HCV–affected participants stated that they had
an incorrectly reduced perception of harms associated
with HCV based on what a GP had told them, or
from the GP’s lack of follow-up or encouragement to
enter treatment. Some participants expressed unease
that clients were not appropriately monitored by GPs,
with blood tests or liver scans, for example.
I took the doctor’s on their word and pretty much
didn’t worry about it. (A+CA)
… doctors are telling people that you know that
they [alanine aminotransferase levels which
indicates liver damage or disease] might be slightly
elevated but “that’s OK so don’t worry about it,” so
they’re not actually giving them information. So as
long as you’re not experiencing symptoms then it’s
OK. (A+CA)
I am aware that some GPs never do bloods and they
don’t seem to monitor people that even if they know
that clients got hep C ….(CA)
Several participants who had delayed antiviral treatment
as a consequence of a perceived lack of GP concern
stated their specialists had indicated that the delay had
caused negative effects on their health by the time they
commenced treatment.
I did ask doctors that question “Is that OK?” and they
would say “Yes” now the specialists say “No mate you
should have had this years ago.” (A+CA)
Perception of benefit: Engagement to access antiviral
treatment
This study was conducted whilst the new DAA treat-
ments were in the trial phase and several participants
who were affected by HCV spoke of the potential of new
treatments to have fewer side-effects, contributing to
their decision to delay consideration of treatment. Par-
ticipants indicated that they would revisit their decisions
regarding antiviral treatment when the new treatment
was available.
They [specialist at tertiary hospital] said that in the
future there’d be medication coming out but at the
moment I can’t get this [interferon-based] medication
because it’s [HCV] not really bad yeah. (A)
Obtaining a referral for treatment by a specialist (required
for previous interferon-based treatment) was the only ra-
tionale provided by many participants for engagement
with a GP about HCV-related issues. Accordingly, patients
deciding against this treatment at the time did not con-
sider any benefit from engagement with GPs about HCV.
I mean the only basic help like that that they [GPs]
could do for you is, you know, is write you out a
referral to somewhere else but I’ve never seeked [sic]
help before for my liver problem because of that
reason. (A)
Negative perceptions and experiences about the physical
side-effects of treatment were relayed by participants
and some had decided that treatment was not currently
an option for them.
One of my friends went on that thing [antiviral
treatment for HCV] to get rid of it but she got really
sick from it ….Yeah it dehydrated her brain; she nearly
died ….(A)
One participant reported that their GP held negative
views of the available, older interferon-based, antiviral
Scarborough et al. BMC Family Practice  (2017) 18:97 Page 7 of 11
treatment and this had led to him refusing to make a
referral for a HCV-related investigation or for antiviral
treatment: “he was quite clear that I shouldn’t have that
…” (A).
Finally, some participants who had sought HCV anti-
viral treatment at tertiary centres cited situations in
which the treatment had not been provided, despite their
GP providing them with the required referral and even
where the GP had actively followed up the progress of
the referral. They recognised that the lack of treatment
provision was the responsibility of the tertiary centre
and not of the GP, but for these participants, engage-
ment with GPs was perceived as an ineffectual pathway
to their goal of antiviral treatment for HCV.
But he’s [the participant’s GP] put referrals in through
the [tertiary hospital #1] but I don’t hear anything
about the referrals, ay. (A)
… you get an appointment and then they [tertiary
liver clinic] pretty much give you a blood test and
then they say “come back in six months.” (A)
Discussion
Since this study was conducted, affordable, direct acting,
antiviral treatment for HCV has become available for
Australian citizens [7] and this represents a spectacular
advance in the potential to address the biomedical aspects
of HCV infection [6]. Most Australians (including all
participants) access private, federally-subsidised GPs for
their healthcare [15] and,for the majority of people with
HCV in Australia, this relatively new treatment can be
delivered via private GPs [13]. For people to access this
treatment, however, they need to disclose their HCV
status or HCV risk factors and be willing to engage with
GPs about this issue. The aim of this study was to better
understand the experiences and perceptions of people
affected by HCV regarding engagement between GPs and
patients about issues relevant to HCV. This information
could be used to guide the development of approaches for
private GPs to reduce barriers to, and improve the delivery
of, care for people with HCV.
Like the general Australian community, people affected by
HCV viewed GPs as a source of general healthcare [13], po-
tentially including issues related to HCV. Several partici-
pants reported being highly satisfied with the care provided
by individual GPs including specific care for their HCV. This
notwithstanding, they and other participants also relayed
negative experiences and perceptions about engagement
with GPs for HCV-related care. Consequently, participants
often described people affected by HCV developing a strat-
egy of “sussing” out doctors before engaging and disclosing
to individual GPs. The process involved weighing up the
perceived risks and the perceived benefits and then deciding
whether engagement and disclosure were worthwhile. As
reported in previous studies [35–40], many of these risks
were related to stigma, but several other factors also contrib-
uted to the decision-making process. If GPs are aware of the
decision-making process that people affected by HCV
undertake, the GPs can utilise strategies aimed at reducing
their doubts and increasing their perceptions of benefit
about the care they will receive, and tip patients’ decisions
towards disclosure and engagement.
Participants acknowledged the difficulties for GPs
dealing with ‘doctor shopping’ and other ‘drug seeking’
behaviour and, particularly where they had previously
participated in it, expressed sympathy for doctors re-
quired to deal with such behaviours. The honest disclos-
ure of current illicit drug use to a GP, however, would be
illogical if the person was attempting to obtain drugs of
dependence without genuine need. This is more likely to
represent an attempt to elicit care for HCV, or a health
issue related to drug use. Faced with this situation, GPs
might offer people a range of information to prevent
harm, for example, brochures regarding prevention of
transmission of blood-borne viruses. In addition to the
benefits for patients receiving opioid substitution treat-
ment [52, 53], GPs may find that drug-seeking behaviour
is reduced when they offer such treatment [45].
Based on their expectations and experiences participants
did not assume that all GPs would be willing to provide
care for HCV-related issues in a non-discriminatory, non-
judgemental way. Importantly, no participant described
overt discrimination associated with HCV by GPs. Dis-
crimination in other settings, including health settings,
was described, and these experiences appeared incorpo-
rated into participants’ expectation of encountering dis-
crimination from GPs. Displaying posters and other
information in the waiting room about hepatitis C or drug
use can signal to patients that the practice is willing to
provide care for these conditions. This material would be
timely as our participants’ responses indicate that when
the new DAA therapies were available, people affected by
HCV would reassess their previous decision to not enter
treatment. Additionally, publicity surrounding these new
treatments may prompt people who are undiagnosed to
consider their risk of exposure, and the presence of this
material in the waiting room may prompt them to seek
testing at the practice.
Upon disclosure of an HCV diagnosis to GPs, some par-
ticipants recounted experiences of unwelcome changes to
their usual care, which precipitated reluctance to disclose
to other practitioners in the future. Unwillingness to pre-
scribe drugs of dependence, and focussing on the patient’s
‘drug-use problem’ were reported by participants as exam-
ples of GPs’ reactions following disclosure of their HCV-
status. Participants expressed a frustration that, whilst well
intentioned, this change appeared to reflect GPs’ incorrect
assumptions concerning ‘inherent’ relationships between
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HCV and ‘current’ drug addiction, when in fact there is a
great deal of heterogeneity of the population affected by
HCV regarding such behaviours or identities [2, 29, 52].
GPs can play an important part in addressing patients’
drug-use issues [54] but should not assume that all pa-
tients presenting for HCV management require treatment
for drug use. Whilst drug addiction is often described as a
‘chronic relapsing disorder’ [55], not all people with HCV
are, or have ever been, addicted to drugs [2, 29, 52]. It is
good practice for GPs to consistently exercise caution pre-
scribing drugs of dependence [55], but the use of these
drugs are warranted to treat many conditions. In these cir-
cumstances, GPs should not deny drugs of dependence to
patients, based on the patient’s HCV status or even re-
ported drug issues, but should exercise clinical judgement
using appropriate safeguards when prescribing [55].
A source of concern for some participants was the loss
of control of their information, with the subsequent risk
to the confidentiality of sensitive information and poten-
tial associated serious consequences. Open disclosure
within the patient-doctor relationship did not equate
with disclosure to family, intimate partners, friends, or
during employment. These participants wanted to avoid
exposure to stigma due to their HCV status and their
past injecting drug behaviour if this became known [31,
39, 56]. Australian general practice standards [57] re-
quire practices to adhere to policies regarding the pro-
tection of patient information. Routinely informing all
patients that these systems are in place, would reduce
fear, and encourage open and honest disclosure, about
sensitive information, in particular drug-related or HCV-
related conditions. Participants wanted to be reassured
by their GP that their information would only be shared
with their explicit permission, and only when relevant.
Even when confidentiality policies are strictly adhered
to, concerns about privacy may still be held by the pa-
tient. Being provided reassurance about this aspect of
care is an important way to address concerns and im-
prove engagement.
Participants recognised the difficulty of GPs maintain-
ing in-depth knowledge over the wide scope of their
work, yet, as reported elsewhere [58], it was common for
participants to be critical of the information provided by
some GPs regarding HCV. It is unsurprising that partici-
pants had a high level of knowledge underpinning this
judgement as many had actively accumulated knowledge
since receiving their HCV diagnosis, had health related
qualifications, and/or worked with clients affected by
HCV. It is important for GPs to be able to demonstrate
up-to-date knowledge about HCV diagnosis, manage-
ment, and treatment to convince people affected by
HCV to engage with them. The DAA treatment for
HCV is relatively simple compared to former treatments
and its availability provides a trigger for GPs to be
recruited into education to bridge GPs’ identified HCV
knowledge gaps [24]. Education must take into account
the time restraints of GPs and incorporate the patient
perspective to barriers to treatment. Where GPs under-
take education and training, it would be useful for
people seeking care to be aware of this through a regis-
ter and/or signage at GP practices.
All people affected by HCV should have access to GPs
providing best practice care for HCV-related issues. This
study has helped to illuminate how the perceptions of
people affected by HCV influences and defines for them
the nature of their engagement with GPs around HCV
care. However, further research could usefully explore
the nature of meanings and perceptions brought to the
potential consultation by GPs, which may enhance or
limit the extent to which they are able to appropriately
and successfully engage with these patients and address
the concerns raised in this paper. This may also allow
the development of practices and policies that better ad-
dress situations where HCV affected patients appear to
have been effectively “banned” from certain South Aus-
tralian practices.
The lack of participants who identify as Indigenous
Australians is a limitation to this study. Further
research with Indigenous Australian participants is ne-
cessary to determine if the findings are applicable to
this population, to identify any additional beliefs or
practices that may contribute to their perspectives and
experiences, and to outline the implications of same for
best practice care [59]. A further potential limitation of
this study is that the findings in one Australian state
(SA) may not be generalizable to jurisdictions where
different systems of primary medical care exist and
other dynamics are present. Experiences of stigma have,
however, been reported internationally [31] and our
findings will be relevant wherever HCV-affected people
face decisions about managing disclosure and engage-
ment when seeking primary healthcare. This study was
conducted before DAA treatments for HCV options be-
came widely available in Australia, and this forms an-
other potential limitation. Although participants
indicated that they would reassess entering treatment
when new DAA treatments became available, people
would need to be assured that they could access this
treatment via GPs; some may not engage and disclose if
they perceive the associated risks to be too high. Un-
derstanding the patient decision-making process re-
garding engagement with GPs will therefore still be
relevant in the era of DAA HCV treatment availability.
Conclusion
People affected by HCV come to any GP-patient inter-
action with a background of experiences and percep-
tions, all of which shape their expectations of the
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benefits and risks of engagement. Capable and willing
GPs may need to act to counteract the perceived risks
and persuade those people “sussing them out” of the
benefits of seeking HCV-related care from them.
To do this, GPs can publicise that they are willing and
able to provide care for HCV and related conditions, in-
cluding making available information about the new
DAA treatment for HCV and its benefits. Stating and
demonstrating adherence to the confidentiality policy of
their practice will reassure patients that they are in con-
trol of their information and that disclosing to the GP
will not increase the risk of exposure to stigma. Each pa-
tient comes to the patient-doctor relationship with their
own history, understandings, and set of needs. GPs can
offer appropriate individualised care to patients affected
by HCV by assessing each individual patient’s situation
and requirements.
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